X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4096) 4096
Publication (246) 246
Book Review (32) 32
Book Chapter (7) 7
Dissertation (5) 5
Book / eBook (1) 1
Conference Proceeding (1) 1
Newspaper Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
vinorelbine (2952) 2952
humans (2867) 2867
oncology (2670) 2670
female (2038) 2038
aged (1802) 1802
chemotherapy (1776) 1776
middle aged (1640) 1640
male (1483) 1483
vinblastine - analogs & derivatives (1434) 1434
lung neoplasms - drug therapy (1383) 1383
antineoplastic combined chemotherapy protocols - therapeutic use (1372) 1372
index medicus (1363) 1363
adult (1316) 1316
carcinoma, non-small-cell lung - drug therapy (1279) 1279
cisplatin (1065) 1065
vinblastine - administration & dosage (1016) 1016
treatment outcome (966) 966
cancer (848) 848
gemcitabine (842) 842
lung neoplasms - pathology (831) 831
docetaxel (704) 704
paclitaxel (703) 703
antineoplastic combined chemotherapy protocols - adverse effects (691) 691
vinorelbine plus cisplatin (691) 691
carcinoma, non-small-cell lung - pathology (687) 687
neoplasm staging (680) 680
deoxycytidine - analogs & derivatives (607) 607
aged, 80 and over (588) 588
trial (584) 584
respiratory system (581) 581
breast neoplasms - drug therapy (562) 562
non-small cell lung cancer (546) 546
lung cancer (531) 531
cisplatin - administration & dosage (521) 521
survival (517) 517
deoxycytidine - administration & dosage (501) 501
carboplatin (499) 499
pharmacology & pharmacy (497) 497
lung neoplasms - mortality (491) 491
lung cancer, non-small cell (474) 474
survival rate (473) 473
survival analysis (463) 463
vinblastine - adverse effects (453) 453
carcinoma, non-small-cell lung - mortality (452) 452
breast cancer (443) 443
therapy (428) 428
antineoplastic agents - therapeutic use (393) 393
drug administration schedule (388) 388
prognosis (385) 385
care and treatment (380) 380
phase-ii trial (378) 378
carcinoma (377) 377
combination (371) 371
disease-free survival (369) 369
breast neoplasms - pathology (358) 358
randomized-trial (346) 346
adjuvant chemotherapy (338) 338
medicine & public health (334) 334
phase-ii (327) 327
vinblastine - therapeutic use (324) 324
paclitaxel - administration & dosage (314) 314
research (313) 313
hematology, oncology and palliative medicine (308) 308
antineoplastic combined chemotherapy protocols - administration & dosage (302) 302
retrospective studies (300) 300
chemotherapy, adjuvant (279) 279
neoplasm metastasis (279) 279
nsclc (277) 277
non-small-cell lung cancer (271) 271
cell lung-cancer (268) 268
carboplatin - administration & dosage (262) 262
phase-iii trial (261) 261
taxoids - administration & dosage (260) 260
antineoplastic agents, phytogenic - administration & dosage (258) 258
dose-response relationship, drug (255) 255
clinical trials (239) 239
metastasis (236) 236
navelbine (231) 231
surgery (230) 230
animals (225) 225
follow-up studies (224) 224
radiotherapy (220) 220
antineoplastic agents, phytogenic - therapeutic use (219) 219
toxicity (218) 218
disease progression (213) 213
deoxycytidine - adverse effects (209) 209
lung neoplasms - surgery (205) 205
quality-of-life (204) 204
capecitabine (202) 202
metaanalysis (200) 200
combined modality therapy (199) 199
drug therapy (199) 199
phase-iii (197) 197
clinical-trials (195) 195
metastatic breast cancer (193) 193
randomized trial (193) 193
doxorubicin (192) 192
combination chemotherapy (189) 189
infusions, intravenous (189) 189
quality of life (188) 188
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3901) 3901
French (97) 97
German (27) 27
Spanish (20) 20
Chinese (17) 17
Italian (9) 9
Japanese (9) 9
Korean (8) 8
Polish (6) 6
Czech (5) 5
Russian (4) 4
Portuguese (3) 3
Arabic (1) 1
Icelandic (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF THORACIC ONCOLOGY, ISSN 1556-0864, 08/2007, Volume 2, Issue 8, pp. 706 - 714
Introduction: The seventh edition of the TNM Classification of Malignant Tumors is due to be published early in 2009. In preparation for this, the... 
SYSTEM | VINORELBINE PLUS CISPLATIN | ONCOLOGY | RESPIRATORY SYSTEM | ASSOCIATION
Journal Article
Journal Article
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 03/2019, Volume 46, Issue 3, pp. 447 - 451
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 2014, Volume 25, Issue 8, pp. 1462 - 1474
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 02/2008, Volume 19, Issue 2, pp. 212 - 222
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 06/2018, Volume 152, pp. 327 - 337
Metronomic vinorelbine (mVNR) has been described primarily as an antiangiogenic therapy, and no direct effects of mVNR on Non Small Cell Lung Cancer (NSCLC)... 
NSCLC | Erlotinib | Metronomic vinorelbine | Gefitinib | Synergism
Journal Article
Asian Pacific Journal of Cancer Prevention, ISSN 1513-7368, 2011, Volume 12, Issue 1, pp. 77 - 80
Objective: To evaluate the efficacy and toxicity of cisplatin and vinorelbine (NP) for postoperative adjuvant chemotherapy of completely resected breast... 
Adjuvant chemotherapy | Breast cancer | Cisplatin | Vinorelbine | adjuvant chemotherapy | FIRST-LINE | CYCLOPHOSPHAMIDE | 1ST-LINE CHEMOTHERAPY | DOXORUBICIN | DOCETAXEL | PACLITAXEL | vinorelbine | THERAPY | ONCOLOGY | INTRAVENOUS VINORELBINE | WEEKLY IV-VINORELBINE | cisplatin | CARCINOMA
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 08/2019, Volume 15, Issue 22, pp. 2561 - 2569
Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome.... 
breast cancer | Navelbine | COMBINATION | chemotherapy | NAME | vinorelbine | CELL LUNG-CANCER | CAPECITABINE | SINGLE-AGENT | metronomic | PHASE-II TRIAL | ONCOLOGY | INTRAVENOUS VINORELBINE | Phase II trial | WEEKLY IV-VINORELBINE | ERIBULIN MESYLATE | 1ST-LINE
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2019, Volume 25, Issue 1, pp. 150 - 157
Purpose: Response to adjuvant chemotherapy after tumor resection varies widely among patients with non-small cell lung cancer (NSCLC); therefore, it is of... 
METAANALYSIS | VINORELBINE PLUS CISPLATIN | ONCOLOGY | STATISTICS | ADENOCARCINOMA | ERCC1
Journal Article
BIOCHEMICAL PHARMACOLOGY, ISSN 0006-2952, 06/2018, Volume 152, pp. 327 - 337
Metronomic vinorelbine (mVNR) has been described primarily as an antiangiogenic therapy, and no direct effects of mVNR on Non Small Cell Lung Cancer (NSCLC)... 
1ST-LINE TREATMENT | NSCLC | PANCREATIC-CANCER | T790M MUTATION | Metronomic vinorelbine | ORAL VINORELBINE | Synergism | CHEMOTHERAPY | BREAST-CANCER | GROWTH-FACTOR RECEPTOR | Erlotinib | PHASE-I TRIAL | ONCOLOGY RESEARCH GROUP | PHARMACOLOGY & PHARMACY | Gefitinib | ELDERLY-PATIENTS
Journal Article
ONCOTARGET, ISSN 1949-2553, 07/2017, Volume 8, Issue 29, pp. 47161 - 47166
Introduction: Using mathematical modelling allows to select a treatment's regimen across infinite possibilities. Here, we report the phase I assessment of a... 
lung cancer | vinorelbine | metronomic | ONCOLOGY | DRUGS | mathematical modeling | PRECISION MEDICINE | mesothelioma | ORAL VINORELBINE | CHEMOTHERAPY | CELL BIOLOGY
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 09/2018, Volume 34, Issue 9, pp. 1687 - 1694
Objectives: Adjuvant chemotherapy (AC) in non-small cell lung cancer (NSCLC) has become a standard of care in patients with stages IIA, IIB, and IIIA after... 
real-world study | Non-small cell lung cancer | survival | adjuvant chemotherapy uptake | MEDICINE, RESEARCH & EXPERIMENTAL | MEDICINE, GENERAL & INTERNAL | CARBOPLATIN | IMPACT | VINORELBINE PLUS CISPLATIN | INTRAVENOUS VINORELBINE
Journal Article
Korean Journal of Dermatology, ISSN 0494-4739, 06/2016, Volume 54, Issue 5, pp. 372 - 376
Journal Article
British Journal of Cancer, ISSN 0007-0920, 02/2018, Volume 118, Issue 3, pp. 344 - 352
Journal Article
The Breast, ISSN 0960-9776, 12/2019, Volume 48, pp. 7 - 16
Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no... 
Cyclophosphamide | Breast cancer | Methotrexate | Metronomic chemotherapy | Vinorelbine
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2018, Volume 36, Issue 2, pp. 315 - 322
Background Dulanermin is a recombinant soluble human Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that activates apoptotic... 
Dulanermin | Objective response rate |